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Abstract
Background: Each year, 10%–20% of patients with tuberculosis (TB) in low- and middle-income countries present with
previously treated TB and are empirically started on a World Health Organization (WHO)-recommended standardized
retreatment regimen. The effectiveness of this retreatment regimen has not been systematically evaluated.
Methods and Findings: From July 2003 to January 2007, we enrolled smear-positive, pulmonary TB patients into a
prospective cohort to study treatment outcomes and mortality during and after treatment with the standardized
retreatment regimen. Median time of follow-up was 21 months (interquartile range 12–33 months). A total of 29/148 (20%)
HIV-uninfected and 37/140 (26%) HIV-infected patients had an unsuccessful treatment outcome. In a multiple logistic
regression analysis to adjust for confounding, factors associated with an unsuccessful treatment outcome were poor
adherence (adjusted odds ratio [aOR] associated with missing half or more of scheduled doses 2.39; 95% confidence interval
(CI) 1.10–5.22), HIV infection (2.16; 1.01–4.61), age (aOR for 10-year increase 1.59; 1.13–2.25), and duration of TB symptoms
(aOR for 1-month increase 1.12; 1.04–1.20). All patients with multidrug-resistant TB had an unsuccessful treatment outcome.
HIV-infected individuals were more likely to die than HIV-uninfected individuals (p,0.0001). Multidrug-resistant TB at
enrolment was the only common risk factor for death during follow-up for both HIV-infected (adjusted hazard ratio [aHR]
17.9; 6.0–53.4) and HIV-uninfected (14.7; 4.1–52.2) individuals. Other risk factors for death during follow-up among HIV-
infected patients were CD4,50 cells/ml and no antiretroviral treatment (aHR 7.4, compared to patients with CD4$200; 3.0–
18.8) and Karnofsky score ,70 (2.1; 1.1–4.1); and among HIV-uninfected patients were poor adherence (missing half or more
of doses) (3.5; 1.1–10.6) and duration of TB symptoms (aHR for a 1-month increase 1.9; 1.0–3.5).
Conclusions: The recommended regimen for retreatment TB in Uganda yields an unacceptable proportion of unsuccessful
outcomes. There is a need to evaluate new treatment strategies in these patients.
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Each year, 10%–20% of patients with tuberculosis (TB) in low-
and middle-income countries present with previously treated TB
and are started on therapy empirically with a standardized five-
drug retreatment regimen as recommended by the World Health
Organization (WHO). It is estimated that annually more than 1
million people in over 90 countries are treated with the 8-mo
regimen (2 mo of streptomycin [S], isoniazid [H], ethambutol [E],
rifampicin [R], and pyrazinamide [Z]; 1 mo of R, H, E and Z;
and 5 mo of R, H and E [2 SHERZ/1 RHEZ/5 RHE]) after
failing, interrupting, or relapsing from prior treatment [1,2].
Unlike treatment regimens for new TB patients, the currently
recommended retreatment regimen (also known as the category II
regimen)hasneverbeenevaluatedforefficacyinrandomizedclinical
trials or prospective cohort studies [3]. The WHO formulated the
recommendationtoaddstreptomycin tothe fourfirst-linedrugsused
for initial therapyfor empiric TB retreatment from expert opinion in
an era prior to the emergence of widespread drug-resistant TB (DR-
TB) and prevalent HIV infection [4]. Recently updated WHO
guidelines recommend drug-susceptibility testing (DST) prior to
retreatment [5] and treatment of confirmed treatment failures and
suspected multidrug-resistant (MDR) TB cases with region-specific
standardized regimens [6]. However, access to DST and to second-
line TB drugs remains poor in high-burden countries and, despite
the findings that inadequate regimens amplify drug resistance
[3,7–9], the standardized retreatment regimen is still generally the
mainstay of national programs in resource-limited settings.
On the basis of WHO surveillance data, retreatment regimens
successfully treat approximately 70% of cases [2]. However, findings
from retrospective studies [1,3,8–22] evaluating the efficacy of the
retreatment regimen,demonstrate a variabletreatment response with
success rates ranging from 26% to 92%. Poor performance has been
attributed to high background rates of DR-TB [1,15,19], prevalent
HIV infection [20], and poor treatment adherence [10,14]. Studies
evaluating the efficacy of the retreatment regimen have generallyonly
assessed outcomes at the completion of therapy and few have
examined the risk for TB recurrence, especially in HIV-infected
people who are likely to be prone to recurrence [23,24]. With
prevalent HIV infection and increasingly recognized DR-TB, there is
a risk for these two conditions to converge in sub-Saharan Africa
creating a ‘‘perfect storm,’’ as recently suggested. [24].
As part of a larger study to assess a new management strategy for
DR-TB in resource-limited settings, we conducted a prospective
cohort study in Kampala, Uganda to assess outcomes in previously
treated TB patients, with particular reference to the impact of drug
resistance on treatment outcomes and survival. We sought to
identify factors associated with poor outcomes and separated our
survival analysis by HIV status, given the overwhelming contribu-
tion of HIV infection to early death, and in order to evaluate the
impact of antiretroviral treatment (ART) and CD4 count on
mortality among TB/HIV coinfected patients. When we began our
study in 2003, Uganda lacked the information, training, and
resources required to address the problem of DR-TB. As part of this
study, we helped the Uganda National Tuberculosis and Leprosy
Programme (NTLP) develop the pillars of a rational and sustainable
program to control DR-TB in Uganda, which included the
provision of treatment with second-line TB drugs when possible.
Methods
Ethics Statement
The AIDS Research Sub-Committee of the Uganda National
Council of Science and Technology and the Institutional Review
Boards at the University of Medicine and Dentistry of New Jersey
and the London School of Hygiene & Tropical Medicine
approved the study.
This study was conducted at the 85-bed inpatient TB ward of
the NTLP Chemotherapy Centre at Mulago Hospital in Kampala,
Uganda. The NTLP Centre serves both as a local treatment clinic
(largest in Kampala) and as the national referral centre
(approximately one-third of attendees are referral cases). Most
(95%) of the retreatment cases seen at the NTLP Centre were
hospitalized to facilitate administration of streptomycin when
clinically possible; however, patients with suspected or known
MDR-TB were managed as outpatients. Uganda is on the WHO
list of high-burden countries with a 2007 estimated annual TB (all
forms) incidence rate of 330 cases per 100,000; 39% with HIV
infection and a prevalence of MDR-TB in new and retreatment
TB cases of 0.5% and 4.4%, respectively [2]. The Ugandan NTLP
reports 100% coverage by directly observed therapy (DOTS), a
case detection rate of 39%, and 70% treatment success rate [2].
All consecutive TB patients hospitalized for retreatment
between July 2003 and January 2007 were eligible for inclusion
in the study, provided they were 18 years or older and gave written
informed consent. Eligible individuals were included in the study if
they provided sputum specimens that were positive for acid-fast
bacilli (AFB) on smear microscopy and TB was confirmed
subsequently by growth of Mycobacterium tuberculosis in culture.
We used a standardized questionnaire to collect demographic and
clinical information. At presentation, participants were classified
according to the WHO definitions of prior treatment outcomes
(relapse, treatment failure, or default) [5] using information from a
previous TB-treatment card (55%) or hospital chart (45%). A
postero-anterior chest radiograph was taken on all study
participants at baseline and an experienced clinician graded the
extent of disease on a four-category ordinal scale. Individuals were
offered HIV testing and a CD4+ lymphocyte cell count was
measured in HIV-infected patients. All patients were offered TB
treatment on the basis of the standard 8-mo WHO-recommended
category II retreatment regimen composed of 2 mo of streptomy-
cin (S), rifampicin (R), isoniazid (H), ethambutol (E), and
pyrazinamide (Z); 1 mo of R, H, E, and Z; and 5 mo of R, H,
and E (2 SRHEZ/1 RHEZ/5 RHE). HIV-infected patients with a
CD4+ cell count less than 200 cells/ml were referred for ART
according to existing national guidelines [25], though access to
ART was limited in Kampala before 2005. Of the 90 individuals
eligible for ART according to this criterion, 45 (50%) received
treatment; eight patients who did not qualify for ART initially,
began treatment with ART later.
Second-line drugs for the treatment of MDR-TB were not
available under routine care by the NTLP when the study was
initiated. After discussions with collaborators, officials from the
Ugandan Ministry of Health, NTLP, WHO, and other stake
holders, we agreed to use our study as an opportunity to build the
necessary foundations for a sustainable MDR-TB program in
Uganda. These included measuring the prevalence of DR-TB,
developing the laboratory capacity for standard and rapid DST,
obtaining preferentially priced second-line TB drugs, training
medical and nursing personnel in MDR-TB management,
developing a community-based DOT program, and establishing
hospital infection control measures. When second-line drugs
became available in 2005, treatment for MDR-TB was begun as
a pilot treatment program and phased in as drugs became
available and conditions allowed. Divided into two groups, a total
of 12 MDR patients received individualized treatment with
second-line drugs (seven of them were included in this study and
five were not included); the first group of patients began treatment
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patients in this study were initially treated with the standard
retreatment regimen at the time they first presented to the clinic
(before their MDR status was known); they all had an unsuccessful
treatment outcome and were included in the survival analysis. The
results from individualized treatment with second-line drugs are
not included in this analysis.
Patients received daily DOT while admitted to the hospital.
After hospital discharge, participants were seen monthly during
their 8-mo TB-treatment course, at month 9, and quarterly
thereafter for the duration of the study. Patients who did not keep
their scheduled visits were traced to their homes. During follow-up
visits, home health visitors assessed treatment adherence through
treatment card review, monthly pill counts, and patient self-report.
Adherence was categorized into a five-level ordinal scale (fully
adherent, missed less then 20% of doses, missed about one half of
the doses, missed most doses, and not adherent at all). The worst
assessment at any visit was taken as the summary measure of
adherence for each participant. Because of small numbers of
patients in some categories, patients were classified as either
‘‘mostly adherent’’ (consisting of the first two categories) or
‘‘missed half or more’’ (consisting of the remaining three
categories). For individuals who died or were lost to follow-up
before the month-3 visit, we were unable to assess adherence.
During follow-up, two sputum samples were collected for AFB
smear microscopy and culture at each of five predefined time
points (months 1, 2, 5, 8, and 12); additional samples were
collected at later visits if patients had a productive cough.
Following WHO treatment outcome definitions [5], participants
were classified as ‘‘cured’’ if they completed treatment and had a
negative culture on solid medium at the end of treatment.
Individuals were classified as having ‘‘completed’’ treatment if they
finished the full 8 mo of therapy and were found to be free of TB
symptoms at their first posttreatment follow-up visit, but had no
culture results at the end of treatment. They were classified as
having an ‘‘unknown’’ outcome if they were lost to follow-up (the
majority of these patients were treatment defaulters). Individuals
were classified as ‘‘treatment failures’’ if they were culture positive
at month 8 or, if they were culture positive at month 5 with no
culture at month 8 and we had no confirmation that they were free
of TB after the end of treatment. At 8 mo, a ‘‘successful’’ TB-
treatment outcome was defined as cure or treatment completion
with no evidence of remaining disease, and ‘‘unsuccessful’’
outcome as treatment failure, death during treatment, or unknown
outcome. During follow up, individuals were evaluated for TB
recurrence and vital status was assessed at the end of scheduled
follow-up, which was 24 mo after the initiation of TB treatment,
or the close of the study.
Laboratory Methods
TB diagnostics. Sputum specimens were processed with the
standard digestion and decontamination method using NALC/Na
citrate/NaOH. Centrifuged pellets were resuspended in a
phosphate buffer solution and used to prepare smears and
cultures on 7H10 agar and liquid media. Sputum smear
microscopy was performed using auramine O fluorescent stain
and reported according to the US CDC microscopy grading
scheme (negative or 1+ to 4+) [26]. Sputum sediments were
cultured in either BACTEC 460 or BACTEC MGIT 960 (Becton
Dickinson Diagnostic Instrument Systems) according to the
manufacturer’s recommendations [27,28]. Confirmation of M.
tuberculosis complex was determined by either the BACTEC NAP
test (Becton Dickinson Diagnostic Instrument Systems) or PCR for
IS6110 as previously described [29]. The number of days from
inoculation of 12B media until positive (growth index .30)
BACTEC culture (day-to-positive [DTP]) was determined for
baseline specimens. Initial M. tuberculosis isolates obtained from
each patient at the time of recruitment were subjected to DST for
S, R, H, E, and Z using BACTEC 460 or MGIT 960. For quality
assurance of DST, 245 specimens were also tested at the CDC
with over 95% concordance. The radiometric BACTEC 460 was
used through July 2006 when it was replaced by the fluorometric
MGIT 960. Most (87%) baseline specimens were cultured using
the BACTEC 460 system and the majority of the initial isolates
tested for drug susceptibility with the 460. The isolation rate and
DTP liquid culture for baseline specimens are comparable with
the BACTEC 460 and MGIT 960 systems. Likewise the DST
results are highly correlative between the two systems. Thus, the
change in methodologies during the study had no impact on the
interpretation of results.
Strain genotyping. We stored the baseline isolate for each
participant and all isolates from patients who had a culture positive
for M. tuberculosis at any time after completing treatment. For each
patient with TB recurrence, we compared the patient’s initial and
recurrent isolates using IS6110 restriction fragment length
polymorphism (RFLP) analysis to differentiate participants with
relapse (identical isolates) from those with reinfection (different
isolates).
HIV testing. HIV testing was offered to all participants; HIV
infection status was determined using a serial rapid test algorithm
in concordance with international guidelines [30]. Determine
(Abbott Laboratories, Abbott Japan Co. Ltd) was used for
screening with positive results confirmed by Statpack (Chembio
Diagnostic Systems). Samples with discordant results were
examined using Unigold (Trinity Biotech PLC). Rare samples
positive by Determine, but negative by Statpack and Unigold,
were resolved by PCR.
Statistical Analysis
The objectives of the statistical analysis were to describe the
treatment outcomes and mortality of HIV-uninfected and HIV-
infected patients and to find factors associated with treatment
outcome and mortality. Logistic regression was used to identify
factors associated with unsuccessful treatment outcome. Factors
were considered for inclusion as risk variables or confounders in
models on substantive grounds, i.e., on the basis of prior
knowledge or biological plausibility [31]. For continuous explan-
atory variables, nonlinearity was tested through the fitting of
fractional polynomials [32]. In order to produce a more
parsimonious model, variables were excluded from the final
model, in a backward elimination type of approach, if they were
not significant at the 15% significance level (in the case of
confounders) or at the 5% significance level in the case of risk
factors, and were not deemed to be sufficiently important to be
retained in the model. In addition, the inclusion of interaction
terms between HIV and the other risk factors was investigated.
Survival analysis methods were used to investigate factors
associated with mortality. Kaplan Meier survival curves were
derived to compare mortality between HIV-infected and HIV-
uninfected patients, and to evaluate the impact of baseline CD4
count and ART treatment on mortality among those HIV-
infected. Cox proportional hazards models were fitted to find
factors associated with mortality. Separate models were fitted for
HIV-uninfected and HIV-infected individuals to allow for
inclusion of CD4+ cell count and ART-status in the model for
HIV-infected individuals. A composite five-level variable for
CD4+ cell count and ART was constructed (CD4$200, CD4
50–199+no ART, CD4 50–199+ART, CD4,50+no ART, and
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cell count and ART. The composite variable of CD4+ cell count
and ART use was analyzed as a time-varying covariate as
individuals initiated ART at different times during follow-up.
Baseline CD4+ cell count was used for all analyses. The
proportional hazards assumption was checked using graphical
methods as well as the test of Grambsch and Therneu [33]. All
analyses were conducted using Stata, release 10.1.
Results
Study Patients
A total of 288 eligible patients, 148 (51%) HIV-uninfected and
140 (49%) HIV-infected, were enrolled in the study between July
2003 and January 2007. Their baseline characteristics are
summarized by HIV status in Table 1. HIV-uninfected patients
were more likely to be male, and to have advanced disease and
cavitations on chest radiograph. HIV-infected patients were older,
presented with a higher average Karnofsky score, and presented
more frequently with constitutional (fevers, rigors, loss of appetite,
malaise, and weight loss) symptoms (not shown in Table 1). The
most common reason for retreatment in HIV-uninfected patients
was defaulting from prior treatment, whereas for patients with
HIV it was for TB relapse. At the time of enrolment, the median
CD4+ cell count in HIV-infected patients was 120 cells/ml
(interquartile range [IQR] 34–287 cells/ml) and 12 (9%) were
receiving treatment with ART.
Baseline Drug Resistance
66 (23%) participants had an M. tuberculosis isolate that was
resistant to at least one first-line antituberculosis drug: 18 (6%) had
MDR, 34 (12%) had mono-resistance to isoniazid, and two (1%)
individuals had mono-resistance to rifampicin. The remaining 12
(4%) individuals had mono-resistance to streptomycin (eight),
ethambutol (three), or pyrazinamide (one). The proportion of
individuals with MDR-TB at baseline was similar for HIV-
uninfected and HIV-infected patients, 11 (7%) and seven (5%),
respectively (p=0.40).
Follow-up of Study Participants
Follow-up results during the 8-mo TB-treatment phase are
summarized by HIV status in Figure 1. After completing TB
treatment, the 240 (83%) individuals retained in the treatment
cohort were followed for a period between 1 and 42 mo, median
21 mo (IQR 12–33 mo). In total, 68 (24%) individuals were lost to
follow-up, 42 (28%) of these were HIV-uninfected individuals and
26 (19%) of these were HIV-infected individuals. The remaining
patients either (a) completed a total of 24 mo of follow-up
(i.e.,16 mo post-TB treatment), (b) were seen at a follow-up visit
during the last 3 mo of the study, or (c) were recorded as having
died during the study.
Treatment Adherence
Patients were admitted for the 2-mo course of injectable
streptomycin treatment for a median duration of 57 d (IQR 53–
61 d), during which time all patients had daily DOT. After
discharge, 217 (75%) individuals were fully adherent or missed a
few doses (less than 5% of individuals) and 59 (21%) missed half or
more of their doses. Adherence could not be measured in 11 (4%)
patients as they either died or were lost to follow-up before the
month-3 visit. Adherence to TB treatment after hospital discharge
did not differ between HIV-uninfected (77%) and HIV-infected
patients (74%) (p=0.64).
TB-Treatment Outcomes and Recurrence
We assessed treatment outcomes at the scheduled completion of
TB therapy and also followed participants for TB recurrence. At
8 mo (Table S1), 29 HIV-uninfected (20%) and 37 HIV-infected
(26%) patients had an unsuccessful treatment outcome (i.e., died
during treatment, failed TB treatment, or unknown outcome). All
18 individuals with MDR-TB had an unsuccessful treatment
outcome: seven died, nine failed treatment, and two had an
unknown outcome at 8 mo. In a logistic regression model
(Table 2), an unsuccessful treatment outcome was associated with
older age, HIV infection, poor adherence, a longer duration of TB
symptoms, and a history of treatment failure. There was no
evidence that mono-resistance to isoniazid (INH) was associated
with an unsuccessful treatment outcome or of an interaction
between HIV and any other risk factor.
A total of 222 (77%) individuals were studied for TB recurrence
(i.e., patients who did not fail treatment or die during the
treatment period and were not lost to follow-up during or
immediately after the 8-mo treatment period); of these, 13 (6%)
had recurrent TB (seven HIV-uninfected, six HIV-infected), a TB
recurrence rate of 4.2 per 100 person-years of observation (PYO).
Among the 12 patients with recurrent TB and available RFLP
results, seven (58%) had reinfection (two HIV-uninfected and five
HIV-infected) and five (42%) had relapse (five HIV-uninfected,
one of whom had isoniazid mono-resistance at baseline and one
HIV-infected).
Survival
Mortality was analyzed from initiation of antituberculous
treatment until the end of follow-up for all patients. In total, 67
patients (23%) died during 511 PYO; 38 (13%) individuals died
during the 8-mo TB-treatment course (Figure 1) and 29 (10%)
after completing treatment (six HIV-uninfected, 23 HIV-infected).
HIV-infected participants (mortality rate 21.4 per 100 PYO) were
more likely to die (p,0.0001) than HIV-uninfected (5.9 per 100
PYO) (Figure 2). Of the 90 HIV coinfected patients who started
the study with CD4 cell counts below 200 cells/ml, 45 (50%) were
able to access ART before the end of the study; 30 (67%) patients
who did not access ART died compared to eight (18%) who did
access ART.
In unadjusted analyses (Table S2), a history of treatment failure,
longer duration of symptoms, and MDR at enrolment were all
factors associated with an increased risk of death in patients with
and without HIV infection; other risk factors for mortality differed
between the two groups. In multivariable analyses (Table 3), the
presence of MDR at the time of enrollment was (a) the only
characteristic common to both HIV-infected and HIV-uninfected
patients and (b) the strongest predictor of mortality (an
approximately 15-fold increase in risk of death). Other factors
associated with death in HIV-uninfected individuals were poor
treatment adherence and longer duration of symptoms prior to
enrollment. For HIV-infected individuals older age, a lower
Karnofsky score, and having a baseline CD4,50 cells/ml and not
initiating ART were also associated with an increased risk of
death.
Discussion
In this prospective cohort study of previously treated pulmonary
TB patients managed under programmatic conditions in Uganda,
we found that 70%–80% of patients with and without HIV
coinfection had a successful treatment outcome at the conclusion
of antituberculous therapy (i.e., cured and completed treatment).
Although this overall response compares well with many other
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status.
Characteristic Level n HIV Uninfected (%)
a (n=148) n HIV Infected (%)
a (n=140) p-Value
b
Age (y) ,30 84 (57) 43 (31)
30–40 37 (25) 67 (48) ,0.001
.40 27 (18) 30 (21)
Mean (SD) 32.6 (11.0) 35.4 (8.6) 0.016
Sex Female 29 (20) 64 (46) ,0.001
Male 119 (80) 76 (54)
Karnofsky Score $70 138 (93) 118 (84) 0.016
,70 10 (7) 22 (16)
Body mass index (kg/m
2) ,15 21 (14) 14 (10)
15–18.5 66 (45) 80 (58) 0.11
.18.5 59 (40) 45 (32)
Mean (SD) 17.9 (2.7) 17.9 (2.5) 0.93
Reason for TB retreatment Relapse 67 (45) 83 (59)
Failure 6 (4) 3 (2) 0.052
Defaulter 75 (51) 54 (39)
Duration of cough prior to enrollment (wk) Median (IQR) 12 (8–20) 12 (6–16) 0.16
Duration of TB symptoms ,3 mo 93 (63) 102 (73)
3–6 mo 35 (24) 26 (19) 0.17
.6m o 2 0( 1 4 ) 1 2( 9 )
Median (wk) (IQR) 12 (8–20) 11 (6–16) 0.12
Number of previous TB episodes 1 128 (86) 114 (81)
2 1 5( 1 1 ) 1 9( 1 4 ) 0 . 4 9
$3 5 (3) 7 (5)
Time since most recent TB episode (mo) Median (IQR) 14 (9–29) 16 (10–37) 0.46
Drug resistance status Sensitive to H and R 118 (80) 116 (83)
Resistance to H or R 19 (13) 17 (12) 0.67
MDR 11 (7) 7 (5)
Extent of disease on chest radiograph Normal 0 9 (7)
Minimal 7 (5) 16 (12) ,0.001
Moderate 29 (20) 48 (35)
Severe 111 (76) 63 (46)
Cavitary disease 121 (82) 70 (51) ,0.001
Miliary infiltrate 4 (3) 3 (2) 0.78
Sputum AFB smear microscopy grade 1+ 2 (1) 5 (4)
2+ 8 (5) 15 (11) 0.16
3+ 19 (13) 21 (15)
4+ 119 (80) 99 (70)
Days-to-positive culture (BACTEC) $7 d 40 (27) 40 (29) 0.77
,7 d 108 (73) 100 (71)
CD4 cell count (cells/ml)
c $350 — 27 (19)
200–349 — 22 (16)
50–199 — 44 (32) n/a
,50 — 46 (33)
Median (IQR) — 120 (34–287)
aUnless specified.
bp-Values based on a chi-squared test for categorical variables and a t-test for continuous variables.
cOne HIV-infected participant did not have CD4 result.
AFB, acid-fast bacilli; CD4, CD4+ T lymphocytes; H, isoniazid; R, rifampicin; n/a, not available; SD, standard deviation.
doi:10.1371/journal.pmed.1000427.t001
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low treatment response rates in certain subgroups of patients and is
associated with poor long-term outcomes, particularly in MDR-
TB and in HIV-infected patients. Initiation of treatment with
ART in eligible patients mitigated much of the excess mortality
associated with HIV infection alone, in agreement with a recent
clinical trial showing that use of ART concurrently with
antituberculous therapy in TB patients is safe and improves
survival [34]. HIV-infected patients with MDR-TB had the
highest death rate, but we could not ascertain if death was a
consequence of advanced HIV disease, TB, or both.
In accordance with the recent review by Menzies and colleagues
[3], this is the first prospective study to evaluate the effectiveness of
the standardized retreatment regimen using accepted outcome
Figure 1. Study profile during the 8-mo TB retreatment period.
doi:10.1371/journal.pmed.1000427.g001
Table 2. Results of fitting multiple logistic regression models for factors associated with unsuccessful treatment outcome
(n=288).
Factor Level Adjusted Odds Ratio
a 95% Confidence Limits p-Value
Age 10-y increase 1.69 1.19–2.41 0.004
HIV status Uninfected 1
Infected 2.44 1.11–5.36 0.026
Baseline resistance status Sensitive to H and R 1
Resistant to H or R 1.63 0.61–4.36 0.33
MDR See footnote b
Reason for TB retreatment Relapse 1
Failure 26.18 1.32–517.7 0.032
Defaulter 1.27 0.59–2.73 0.54
Treatment adherence Mostly adherent
c 1
Missed half or more 2.43 1.09–5.40 0.030
Duration of TB symptoms 1-mo increase 1.12 1.04–1.20 0.003
aOdds ratios adjusted for other terms in the model including HIV status, drug resistance status, duration of TB symptoms, age, sex, adherence, and duration since last TB
episode.
bAll patients with MDR had an unsuccessful outcome so the odds ratio cannot be estimated; 18 observations were thus omitted from the model.
cCategory includes participants that were fully adherent with treatment and those that missed a few doses.
H, isoniazid; R, rifampicin.
doi:10.1371/journal.pmed.1000427.t002
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over 90 countries, there is growing concern that this therapeutic
strategy leads to amplification of drug resistance and poor
treatment outcomes [1,3,23,36]. Previous studies were limited by
their retrospective design and use of unstandardized outcome
measures [35]. Our use of programmatic end-points backed by
culture results overcomes the potential biases inherent in
retrospective studies. The 70%–80% treatment success rate we
observed is broadly in agreement with results from the 1980s [4], a
large multiyear (1996–2003) study from Morocco [15], and a small
Figure 2. Kaplan-Meier curves by HIV status.
doi:10.1371/journal.pmed.1000427.g002
Table 3. Mortality: results of fitting Cox proportional hazards regression models by HIV status.
Factor Level HIV Uninfected (n=148)
a HIV Infected (n=140)
b
Hazard Ratio (95% CI) p-Value Hazard Ratio (95% CI) p-Value
Resistance status Sensitive to H and R 1 — 1
Resistant to H or R 2.2 (0.4–11.1) 0.33 1.4 (0.6–3.3) 0.41
MDR 14.7 (4.1–52.2) ,0.001 17.9 (6.0–53.4) ,0.001
Duration of TB symptoms 1-mo increase 1.9 (1.0–3.5) 0.05 — —
TB-treatment adherence Mostly adherent
c 1— —
Missed half or more 3.5 (1.1–10.6) 0.027 — —
Age 10-y increase — — 1.4 (0.99–1.9) 0.059
Karnofsky score $70 — — 1
,70 — — 2.1 (1.1–4.1) 0.019
Baseline CD4 (cells/ml) and ART use CD4$200 n/a n/a 1
CD4 50–199, no ART — — 1.9 (0.7–5.0) 0.17
CD4 50–199, ART — — 1.2 (0.3–4.6) 0.80
CD4,50, no ART — — 7.4 (3.0–18.8) ,0.001
CD4,50, ART — — 2.1 (0.7–6.7) 0.20
aFor HIV-uninfected participants, the potential risk factors considered were resistance status, adherence to TB treatment, duration of TB symptoms, reason for being
retreated, and BACTEC days to positivity at baseline, with age and sex as potential confounders.
bFor HIV-infected participants, the potential risk factors and confounders considered were as for HIV-uninfected with in addition a composite factor measuring baseline
CD4 count and ART status; this factor has five levels namely ‘‘CD4$200,’’ ‘‘CD4 50–199+no ART,’’ ‘‘CD4 50–199+ART,’’ ‘‘CD4,50+no ART,’’ and ‘‘CD4,50+ART.’’
cCategory includes participants who were fully adherent with treatment and those that missed a few doses.
CI, confidence interval; H, isoniazid; n/a, not available; R, rifampicin.
doi:10.1371/journal.pmed.1000427.t003
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significantly better than much of the published evidence [1,10,
12–14,16,19,20,22].
This wide variability is mainly explained by differences in the
relative frequency of three prognostic factors across study
populations, which include the levels of treatment adherence,
MDR-TB, and HIV infection. Among these factors, MDR-TB
seems to have a prominent influence on the efficacy of the
retreatment regimen as shown in the ecological study by Mak and
colleagues [1], where the treatment success rate was significantly
decreased as the prevalence of MDR reached a tipping point of
3%, beyond which the failure rate doubled from 5% to 10.6%
(p,0.0001). In this study, all patients with MDR, especially those
with HIV, not surprisingly did poorly given the composition of the
retreatment TB regimen. However, comparatively few patients
had baseline MDR and thus, the overall attributable risk of MDR
to poor TB-treatment outcomes or death was only 27%. Further-
more, other forms of DR-TB such as mono-resistance to isoniazid
or rifampicin, present in approximately 20% of the cohort, did not
predict treatment outcome or survival.
Taken together, the available data show that the retreatment
regimen is effective in treatment of adherent patients with pan-
susceptible or mono-resistant M. tuberculosis, resulting in acceptable
clinical outcomes in most retreatment cases at the conclusion of
TB therapy. However, despite these relatively short-term optimis-
tic findings, this cohort of retreatment TB patients experienced
poor long-term outcomes. In this sub-Saharan African program-
matic setting, of the patients studied for TB recurrence after
satisfactory completion of TB treatment, 6% had TB recurrence
while a further 9% died, and 18% were lost to follow-up. In
addition seven patients who had an unsatisfactory outcome at
month 8 (either treatment failure or unknown outcome) later died.
This finding, which has been previously reported [17,23], but is
infrequently discussed in the literature, suggests caution when
interpreting standard success rates determined at the conclusion of
TB treatment. Furthermore, although limited by small numbers,
our RFLP results suggest caution in the continued programmatic
use of the term ‘‘relapse’’ to describe all patients with TB recu-
rrence and, that strategies to prevent recurrence after comple-
ting treatment may be different for HIV-uninfected (mostly
relapses) and HIV-infected (mostly reinfection) TB patients in
Uganda. Further research is needed to understand the determi-
nants of long-term prognosis in TB patients in sub-Saharan Africa
and evaluate which, if any, of the known risk factors associated to
poor outcomes are modifiable.
The poor prognosis of retreatment TB patients is usually
ascribed to undiagnosed DR-TB and this is leading to a long
overdue improvement in laboratory and treatment capacity in
resource-limited settings. However, there is a need to further
understand if the rapid death (within 1–3 wk after presentation)
observed in some patients with HIV/AIDS and DR-TB is a
consequence of advanced HIV disease, suboptimally treated TB,
or both [37,38]. In addition, further outcomes-based studies are
required to evaluate the efficacy, safety, and cost-effectiveness of
early detection of DR-TB using rapid DST testing methods in
populations with variable rates of DR-TB and HIV/AIDS. It is
likely that the best strategy will involve rapid and adequate
treatment of both DR-TB (with new, more effective treatment
regimens) and HIV disease [34]. Lastly, our results add to the large
body of evidence showing that the provision of DOT should be a
major priority in any TB-treatment strategy.
At the annual collaborator’s meetings in Kampala, our group
had long and impassioned discussions regarding one very difficult
ethical dilemma we faced: in a setting such as Uganda where
second-line TB drugs are not routinely available, can research in
MDR-TB be ethically sound? Although a profound debate on this
issue would be beyond the scope of this manuscript, we believe it is
important to provide the reader with a summary of our thinking
and our actions. Our discussions focused on possible alternatives to
our study design and the provision of treatment with second-line
drugs considering the time, cost, and complexities involved in
building an MDR-TB–treatment program. We considered three
alternate designs. Excluding known or suspected MDR patients
(and other resistance patterns that are likely to fail treatment or
relapse with the retreatment regimen) would have significantly
reduced the generalizability of our results and excluded the very
population that ‘‘exposes’’ the limitations of the regimen we
intended to evaluate. We also considered withholding DST results
performed at enrolment, but we reasoned this would have only
artificially lessened the ethical concerns we had. Finally, we
considered discontinuing the study of MDR-TB patients at the
time their DST results became available. During our discussions, it
became evident that none of these options would have improved
the care of study participants and rather, would prevent them from
the benefits of research participation, including the eventual access
of some of them to second-line drugs. Even before second-line
drugs became available through our program, we are confident
patients benefited from study participation both directly (improved
treatment and reduced toxicity) and indirectly (patient education
and reduced transmission) when compared to existing standard of
care in Uganda. With no access to second-line drugs and a
prevalence three times higher then expected [36], we were
surprised and concerned at the amount of MDR-TB that we
discovered, and we immediately tried to find ways to treat these
patients. Benefiting from the significant expertise and knowledge
on MDR-TB of collaborators and consultants attending our
meetings, our group carefully considered the best strategy to
initiate and coordinate an MDR-TB–treatment program with the
NTLP. At that time, we were unaware of any other MDR-TB
programs in sub-Saharan Africa (other than those in South Africa)
to help guide our actions. One option we considered was to focus
on the immediate, yet costly and likely unsustainable provision of
MDR-TB–treatment using imported personnel, technologies, and
drugs. This approach, in fact, led to effective community
mobilization to sustain an MDR-TB program in Peru [39];
however, Uganda differs from Peru as it has a lower burden of TB
and of HIV and almost 10-fold higher gross domestic product
(GDP) per capita. An alternate strategy we debated was to place
priority on building, from the ‘bottom up’, the necessary
foundations for a sustainable program, while treating as many
MDR-TB patients as possible. Although we recognize neither of
these options is ideal, we decided to pursue the second option
because of the input from Ugandan collaborators attending our
annual meetings; as the study progressed and data became
available, our decisions were based on consensus and compromise.
The challenges we faced were enormous, but these are not limited
to Uganda as even in 2010, it is estimated that less than 2% of
MDR-TB patients in the world have access to adequate treatment
[40,41]. Our hope is that our data-driven call to improve MDR-
TB management acts as a powerful complement to two recent
editorials advocating for such a change [40,41].
Our results should be interpreted in the context of the study
design and its limitations. Our design may have biased findings
towards improved outcomes when compared to true program-
matic conditions for several reasons. Firstly, because the clinic
attempted to manage patients with suspected MDR-TB as
outpatients in an effort to reduce nosocomial transmission, this
study did not include all MDR-TB patients diagnosed at this site
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TB patients we have reported elsewhere [36], would have
decreased the treatment response rate of this study. Secondly,
given that this study only included hospitalized patients with daily
DOT during the intensive treatment phase and improved follow-
up after discharge (presumably resulting in improved treatment
outcomes), the inclusion of all retreatment TB patients at this site
would have surely resulted in more unfavorable outcomes. Finally,
our study required patients to be smear and culture positive; the
inclusion of smear-negative individuals, which is more frequently
seen in advanced HIV-infected patients, may have lowered the
treatment success rate of this cohort. Also, all deaths in the study
were considered as unfavorable outcomes of TB retreatment. We
did not determine the cause of death of individuals who died and
this may have inflated the mortality associated with retreatment,
particularly for HIV-infected patients. Also, after completion of
TB treatment, retention dropped with approximately 20% of
patients lost to follow-up after completing TB treatment. The
analysis assumed that these patients had the same survival
experience as other patients; however, on the basis of our prior
experience, it is probable that the population lost to follow-up
experienced greater mortality. If true, the actual mortality may be
greater than estimated due to this differential loss. We believe,
however, our results provide a true reflection of outcomes in a
programmatic setting in sub-Saharan Africa and none of these
factors would invalidate the conclusions of this study.
The results of this prospective study provide evidence that the
standard retreatment approach to TB, as implemented in low- and
middle-income settings, is inadequate. Improved access to rapid
diagnostics for TB drug resistance, second-line TB treatment, and
antiretroviral therapy is urgently needed, but the evidence base
guiding the utilization of these tools by clinicians and planners
remainssparse.Ashasbeenadvocated [1,7,42], clinicaltrials ofnew
approaches to retreatment TB in areas heavily affected by HIV and
TB should be a priority. Our findings indicate the importance of a
new, more effective strategy for the management of DR-TB in low-
and medium-income settings with prevalent HIV infection.
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Background. One-third of the world’s population is
currently infected with Mycobacterium tuberculosis, the
bacterium that causes tuberculosis (TB), and 5%–10% of
HIV-uninfected individuals will go on to develop disease and
become infectious. The risk of progression from infection to
disease in HIV infected is much higher. If left untreated, each
person with active TB may infect 10 to 15 people every year,
reinforcing the public health priority of controlling TB
through adequate treatment. Patients with a previous
history of TB treatment are a major concern for TB
programs throughout the world because these patients are
at a much higher risk of harboring a form of TB that is
resistant to the drugs most frequently used, resulting in
poorer treatment outcomes and significantly complicating
current management strategies. More then 1 million people
in over 90 countries need to be ‘‘re-treated’’ after failing,
interrupting, or relapsing from previous TB treatment.
Every year, 10%–20% of people with TB in low- and middle-
income countries are started on a standardized five-drug
retreatment regimen as recommended by the World Health
Organization (WHO). Yet, unlike treatment regimens for
newly diagnosed TB patients, the recommended retreatment
regimen (also known as the category II regimen) has never
been properly evaluated in randomized clinical trials or
prospective cohort studies. Rather, this regimen was
recommended by experts before the current situation of
widespread drug-resistant TB and HIV infection.
Why Was This Study Done? WHO surveillance data
suggest that the retreatment regimen is successful in about
70% of patients, but retrospective studies that have
evaluated the regimen’s efficacy showed variable treatment
responses with success rates ranging from 26% to 92%.
However, these studies have generally only assessed
outcomes at the completion of the retreatment regimen,
and few have examined the risk of TB recurrence, especially
in people who are also infected with HIV and so are more
likely to experience TB recurrence—an issue of particular
concern in sub-Saharan Africa. Therefore, in this study based
in Kampala, Uganda, the researchers conducted a
prospective cohort study to assess treatment and survival
outcomes in patients previously treated for TB and to
identify factors associated with poor outcomes. Given the
overwhelming contribution of HIV infection to death, the
researchers categorized their survival analysis by HIV status.
What Did the Researchers Do and Find? The researchers
recruited consecutive smear-positive TB patients who were
admitted to Mulago Hospital, Kampala, Uganda, for the
retreatment of TB with the standard retreatment regimen
between July 2003 and January 2007. Eligible patients
received daily directly observed therapy and after hospital
discharge, were seen every month during their 8-month TB-
retreatment course. Home health visitors assessed treatment
adherence through treatment card review, monthly pill
counts, and patient self-report. After the completion of the
retreatment regimen, patients were evaluated for TB
recurrence every 3 months for a median of 21 months. The
researchers then used a statistical model to identify
treatment outcomes and mortality HIV-uninfected and HIV-
infected patients.
The researchers found that 29/148 (20%) of HIV-uninfected
and 37/140 (26%) of HIV-infected patients had an unsuc-
cessful treatment outcome. Factors associated with an
unsuccessful treatment outcome were poor adherence, HIV
infection, increasing age, and duration of TB symptoms. All
patients with multidrug resistant TB, a form of TB that is
resistant to the two most important drugs used to treat TB,
had an unsuccessful treatment outcome. In addition, HIV-
infected subjects were more likely to die than HIV-uninfected
subjects (p,0.0001), and having multidrug resistant TB at
enrollment was the only common risk factor for death during
follow-up for both HIV-infected and HIV uninfected patients.
Other risk factors for death among HIV-infected patients
were CD4,50 cells/ml and no antiretroviral therapy treat-
ment and among HIV-uninfected patients were poor
adherence and duration of TB symptoms.
What Do These Findings Mean? The researchers found
that although 70%–80% of patients had a successful
treatment outcome on completion of antituberculous
therapy (a result that compares well with retrospective
studies), the standard retreatment regimen had low
treatment response rates and was associated with poor
long-term outcomes in certain subgroups of patients,
particularly those with multidrug resistant TB and HIV.
These findings indicate that the standard retreatment
approach to TB as implemented in low- and middle-income
settings is inadequate and stress the importance of a new,
more effective, strategies. Improved access to rapid diag-
nostics for TB drug-resistance, second-line TB treatment, and
antiretroviral therapy is urgently needed, along with a strong
evidence base to guide clinicians and policy makers on how
best to use these tools.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000427.
N The World Health Organization has information on TB, TB
retreatment, and multidrug-resistant TB
N WHO also provides information on TB/HIV coinfection
N The Stop TB Partnership provides information on the
global plan to stop TB
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